Clinical trials: Allogenic Disease
Hematological Diseases
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of…
- Trial name
- BX-PK (NCT02483325)
- Testing
- Allogeneic transplant conditioning
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Paoli-Calmettes
Acute Lymphoblastic Leukemia, Stem Cell Transplantation, Hematopoietic
Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
Evolving paradigms in the treatment of adult ALL include the application of intense pediatric regimens to the treatment of adolescents and young adults (AYA) and the optimization of allogeneic hematopoietic stem cell…
- Trial name
- NCT01457040
- Testing
- TBI+CY+VP-16, FA+TBI+CY+VP-16
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
ALS - Amyotrophic Lateral Sclerosis
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
This study is testing whether giving people with ALS specially matched immune cells called B cells from a related donor is safe. Up to 10 participants will each receive two B cell infusions at least 60 days apart.
- Trial name
- NCT07838389
- Testing
- B cell infusion
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mark Poznansky
Acute Lymphoblastic Leukemia (ALL)
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting…
- Trial name
- NCT02338050
- Testing
- Moxetumomab Pasudotox
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or…
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma
- Trial name
- NCT02424968
- Testing
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Idiopathic Scoliosis, Transfusion Reaction
Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood
A prospective study designed to evaluate changes in tissue and cerebral oxygenation before and following administration of blood for patients undergoing spinal surgery.
- Trial name
- NCT02607150
- Testing
- Cerebral Oxygenation Changes
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Graft-versus-host Disease (GVHD)
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood…
- Trial name
- NCT06615050
- Testing
- Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux)
- Where
- 30 sites in United States
- Volunteers
- 572 people
- Sponsor
- Incyte Corporation
Kidney Cancer
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00006968
- Testing
- filgrastim, cyclosporine, pentostatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Graft-versus-host Disease
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral…
- Trial name
- NCT05622318
- Testing
- Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Medical College of Wisconsin
AL Amyloidosis
Allo SCT in Amyloidosis Non-interventional Study
Light-chain (AL-) amyloidosis is a very rare monoclonal plasma cell disorder with poor prognosis. Rarity of disease has precluded performance of randomized controlled trials comparing various possible treatment modalities.
- Trial name
- NCT02257905
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Treatment Resistant Depression
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
This study is intended to evaluate the safety and potential efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo in patients with Treatment Resistant Depression.
- Trial name
- ANU (NCT02675556)
- Testing
- Allo-hMSCs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joshua M Hare
Periodontal Diseases
Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy
The purpose of this study is to evaluate the safety of clinical injection of allogeneic human dental pulp stem cell(DPSC) in local infected periodontal tissue and determine whether injection of allogeneic DPSC is a effective way…
- Trial name
- NCT02523651
- Testing
- DPSC injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Songlin Wang
Graft-versus-host Disease, Hematological Malignancies
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
The aim of this study is to evaluate the efficacy and safety of anti-thymocyte globulin combined with PTCy (post-HSCT cyclophosphamide, PTCy) in preventing graft-versus-host disease (GVHD) in allo-HSCT patients after…
- Trial name
- NCT06238245
- Testing
- Cyclophosphamid
- Volunteers
- 22 people
- Sponsor
- Beijing 302 Hospital
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004181
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Northwestern University
Chronic Graft-versus-host-disease
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
This study is being done in patients who have been receiving corticosteroids or other immunosuppressive therapies for the treatment of cGVHD for at least 6 months.
- Trial name
- NCT04200365
- Testing
- Itacitinib
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
This pilot clinical trial studies the side effects of lenalidomide and ipilimumab after stem cell transplant in treating patients with hematologic or lymphoid malignancies.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT01919619
- Testing
- Ipilimumab, Lenalidomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia in Remission
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Relapse remains the main cause of death in patients with myeloid malignancies, especially after an allotransplant. Using drugs with higher anti-leukemic activity as part of the conditioning regimen is one of the strategies to…
- Trial name
- FLUCLORIC (NCT05917405)
- Testing
- Fludarabine, Busulfan, ATG
- Where
- 23 sites in France
- Volunteers
- 302 people
- Sponsor
- Nantes University Hospital
Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor.
- Conditions
- Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk, Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
- Trial name
- ECT-001-CB-013 (NCT07301866)
- Testing
- ECT-001-CB
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Crohn's Disease
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease
Allogeneic transplantation has been a high-risk procedure, although non-myeloablative conditioning regimens (mini-transplantation) minimizes regimen related toxicity.
- Trial name
- NCT01288053
- Testing
- Allogeneic Stem Cell Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.